artificial intelligence in drug discovery

News
Owkin

Ex-BioMarin CEO Bienaimé re-emerges at Owkin

Just four months after ending an 18-year stint as chief executive of BioMarin, Jean-Jacques Bienaimé, has been named chairman of Owkin, a specialist in applying artificial

Digital
AI in drug discovery

AI in Drug Discovery: Day One

There is no denying that artificial intelligence (AI) has captured the imagination of innovators working across the pharmaceutical sector.